Collaboration with AdventHealth for two studies

AI SummaryClose X

CelLBxHealth plc has announced a collaboration with AdventHealth, a large US health system, to utilize its Parsortix platform in two clinical studies, ACTION and SUNRISE, focusing on colon, gastrointestinal, and lung cancers. These multi-centre studies will involve 219 patients in ACTION and 120 patients in SUNRISE, employing circulating tumour cell (CTC) analysis as a correlative endpoint to monitor treatment response and tumour biology non-invasively. This partnership aims to validate and expand the adoption of CelLBxHealth's liquid biopsy technology within a significant healthcare network, potentially improving patient-centric care and addressing health inequalities by bringing advanced cancer monitoring closer to patients.

Disclaimer*

UK 100

Latest directors dealings